Valeant Pharma (NYSE: VRX) announced that the ad hoc committee appointed by Valeant's board of directors has appointed ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Management Changes Management Comments

Valeant Pharmaceuticals (VRX) Bull-Bear Debate RagesOctober 30, 2015 12:57 PM Bill Ackman said Valeant Pharma (VRX) worth $180-$240 Near-Term, $262-$350 Long-TermOctober 30, 2015 10:14 AM Valeant Pharma (VRX) on Watch as Ahead of Pershing Square Conference CallOctober 30, 2015 8:53 AM Former Deputy Attorney General Appointed To Advise Valeant's Ad Hoc CommitteeOctober 30, 2015 8:00 AM